NVS - Iovance Biotherapeutics: Solving The Solid Tumors Conundrum
Introduction
I have covered companies developing immunotherapy treatments, with a focus on T cell therapies. While I have no doubt T cell therapies will be the next pillar in cancer treatments, current generation of therapies are plagued with various limitations. For example, approved CAR Ts such as Kymriah from Novartis (NVS) and Yescarta from Gilead Sciences (GILD) have had limited commercial success since their launch.
This is because such treatments are autologous and are derived from the patient's own T cells, which make it highly personalized, and hard to manufacture which